The 340B Program was created to provide medicine to patients who might otherwise not be able to afford it – but drug manufacturers see its current, expansive state as unsustainable. What’s the balance between discounted drugs and patient access, and will the Supreme Court end up with the final say?
What Is 340B?
Named after section 340B of the Public Health Service Act, the 340B Program was established by an act of Congress in 1992. The intent of 340B was to provide price relief to hospitals that disproportionately serve low-income populations:
• Disproportionate share hospitals (DSHs)
• Children’s hospitals and cancer hospitals exempt from the Medicare prospective payment system
• Sole community hospitals
• Rural referral centers
• Critical access hospitals
The program serves these types of hospitals and extends to their “child” sites, which include any “clinic/department/offsite facility that is eligible to participate in the 340B Program because it is an integral part of a hospital that participates in the program, as evidenced by the fact that it is reimbursable on the hospital’s Medicare cost report.” Read more >
With 10,000 pharmacies reaching 8 million+ patients monthly, RedSail Technologies is the leader in pharmacy software and data solutions and services – empowering pharmacy and transforming care. Part of the country’s most clinically advanced and financially sustainable pharmacy network, RedSail customers receive the integrated tools and connectivity needed for success, freeing them for patient care. RedSail's customers include community, long-term care, outpatient, HME/DME, and specialty pharmacies alongside pharma, payer, and strategic industry partners. We offer solutions for pharmacy operations, transactional and medical billing services, and patient engagement and education through our brands including PioneerRx®, Axys®, PowerLine®, and QS/1®.
This post is related to:
340B Solutions, 340B Management Systems
